Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioGaia AB ( ($SE:BIOG.B) ) has issued an announcement.
BioGaia AB has launched a new subsidiary, BioGaia New Sciences AB, to advance microbiome research beyond its core areas, focusing initially on skin health. This move aligns with the growing skin microbiome market, projected to reach USD 2.86 billion by 2032, and reflects BioGaia’s strategy to expand its science-backed product offerings in response to increasing consumer demand for microbiome-specific skincare solutions.
More about BioGaia AB
BioGaia is a Swedish probiotics company with over 35 years of experience in microbiome research. It develops, markets, and sells probiotic products focusing on gut health, immune health, and oral health, distributed in over 100 markets. The company’s class B shares are listed on the Mid Cap segment of Nasdaq Stockholm.
Average Trading Volume: 199,356
Current Market Cap: SEK10.86B
For a thorough assessment of BIOG.B stock, go to TipRanks’ Stock Analysis page.